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Background: There are a few nutritional approaches to address the increased needs of managing diabetic
conditions. Previously it has been reported that UP780, a standardized composition of aloe chromone formulated
with an aloe polysaccharide, has a significant impact in reducing HbA1C, fasting blood glucose, fructosamine and
plasma insulin level in humans and improved impaired glucose and insulin resistance in high-fat diet-induced and
db/db non-insulin dependent diabetic mouse models. Here we describe activity of UP780 and its constituents to
improve insulin sensitivity in alloxan induced insulin dependent diabetic mouse model.
Materials and method: Insulin dependent diabetes was induced by administering a single intraperitoneal injection of
alloxan monohydrate at a dose of 150 mg/kg to CD-1 mice. Aloesin (UP394) was formulated with an Aloe vera inner
leaf gel powder polysaccharide (Qmatrix) to yield a composition designated UP780. Efficacy of oral administration of
UP780 at 2000 mg/kg and its constituents (aloesin at 80 mg/kg and Qmatrix at 1920 mg/kg) were evaluated in this
model. Glyburide, a sulfonylurea drug used in the treatment of type 2 diabetes, was used at 5 mg/kg as a positive
control. Effect of UP780 on non-diabetic normal mice was also addressed.
Results: Mice administered intraperitoneal alloxan monohydrate developed progressive type-1 diabetes like symptom.
After 4 weeks of daily oral administration, reductions of 35.9%, 17.2% and 11.6% in fasting blood glucose levels were
observed for UP780, the UP780 Aloe vera inner leaf gel polysaccharide preparation without chromone (Qmatrix), and
Aloesin (UP394), treated animals respectively, compared to vehicle treated animals. UP780 has no impact on blood
glucose level of non-diabetic healthy mice. UP780 showed statistically significant improvement for blood glucose
clearance in oral glucose tolerance tests. Similarly, enhanced improvement in plasma insulin level and statistically
significant reduction in triglyceride level was also observed for animals treated with the composition.
Conclusion: These findings suggest that UP780, a chromone standardized Aloe based composition, could possibly be
used as a natural supplement alternative to facilitate maintenance of healthy blood glucose levels.
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Ethnobotanical archives reveal that more than 800 plants
have been used as an alternative remedies for the treat-
ment of high blood glucose associated human ailments
with minor or no scientific evidence. It’s not uncommon
to find Aloe as an alternative solution in this front line for
many years. Aloe is a biochemically complex plant that
contains many biologically active substances [1]. Histori-
cally, Aloe products have been used in dermatological* Correspondence: myimam@unigen.net
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These uses have stimulated a great deal of research in
identifying polysaccharides, chromones, anthraquinones
and other compounds from Aloe plants that have clinical
implications as anti-inflammatory [2,3] anti-tumor, anti-
gastric ulcer, anti-diabetic, anti-tyrosinase [4] and antioxi-
dant activity [5].
Aloe vera, also with a Latin name Aloe barbadensis,
leaves and their bitter principles exhibit effects on blood
glucose level in normal and alloxan-induced diabeticLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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strates anti-diabetic activity in clinical studies [7].
Chromones are a specific type of aromatic compounds
having a benzopyran-4-one as their major skeletal struc-
ture as illustrated by the Figure 1. Chomones isolated
from various Aloe species have been reported to have
diverse biological activity. Aloesin have reportedly in-
hibited tyrosinase activity [8] and up-regulate cyclin
E-dependent kinase activity [9]. Those chromones iso-
lated from Aloe barbadensis also demonstrate anti-in-
flammatory [10] and antioxidant activity [11].
A large diversity of animal models has been developed
to better understand the pathogenesis of insulin de-
pendent diabetes and new drugs have been introduced
into the market to treat the primary cause or to prevent
the catastrophe of its complications. Among these models,
alloxan induced diabetes model is by far the most fre-
quently used model which has been useful for the study of
multiple aspect of the disease [12,13].
Alloxan, as a cytotoxic agent to the insulin-secreting
β cells of the pancreas, effectively induces insulin
dependent phenotypes that resemble type 1 diabetes or
post-beta cell “burnout” type 2 diabetes in a wide variety
of animal models [12,13]. Thus, it allows elucidation of
antihyperglycemic agents in the treatment of diabetes.
Alloxan-induced diabetes consistently produced theFigure 1 HPLC chromatograph of Aloesin (UP394).main characteristics of diabetes mellitus including poly-
dipsia, polyphagia, polyuria, decreased insulin levels,
weight loss and hyperglycemia.
Though lifestyle intervention, mainly diet and exercise,
remain as the ultimate behavioral change in managing
metabolic syndrome and diabetic conditions; it is desi-
rable to have safe nutritional approaches for preventing
and/or ameliorating insulin resistance. In this frontier
use of dietary supplements could be a potential option
to control diabetic conditions. To date, many plant de-
rived extracts have been studied, reported and commer-
cialized for glucose lowering effects. However, very few
of them are supported by credible chemical profiles,
pre-clinical and clinical trial data to support associated
claims.
The present study was therefore designed to evaluate a
standardized composition, UP780, an aloe chromone
formulated with an aloe polysaccharide, improves insulin




Purpose bred female CD-1 mice, weighing 18-24 g, were
purchased from USDA approved laboratory animal
vendor (Charles River Laboratories, Inc., Wilmington,
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cages were identified with a cage card indicating project
number, test article, dose level, group, and animal num-
ber. The Harlan T7087 soft cob beddings was used and
changed at least twice/week. Animals were provided
with fresh water and rodent chow diet # T2018 (Harlan
Teklad, 370 W, Kent, WA) ad libitum and were housed
in a temperature controlled room (22.2°C) on a 12 hour
light-dark cycle. All animal experiments were conducted
according to institutional guidelines congruent with the
guide for the care and use of laboratory animals. All ani-
mal experiments were conducted according to institu-
tional guidelines congruent with the guide for the care
and use of laboratory animals. IACUC approval refe-
rence #: UAS-101205.
Model induction and dosing
To induce disease model, overnight fasted mice received a
single injection of alloxan monohydrate (Sigma Chemical,
St. Louis, OH) at a dose of 150 mg/kg body weight in-
traperitoneally [12,13]. The induction of alloxan-induced
diabetes was confirmed by measuring blood glucose level
on the 5th day after alloxan administration. Mice with glu-
cose levels above 200 mg/dl were selected for randomized
grouping. Average blood glucose levels for the groups
ranged between 368 – 389 mg/dl. Two group of mice
(n = 15/group) which did not receive alloxan served as the
non-diabetic control (one group treated with vehicle and
the other group treated with UP780 at 2000 mg/kg).
Once an induction of the disease was confirmed and
randomization was completed, daily oral treatment was ini-
tiated. Fresh test compounds and positive control were pre-
pared each day and delivered orally to mice (N = 15) at a
dose of 2000 mg/kg standardized composition (UP780),
1920 mg/kg Aloe vera inner leaf gel powder polysaccha-
ride (Qmatrix) and 80 mg/kg chromone aloesin (UP394)
(Figure 1). Previously we have shown 200 mg/kg as the ef-
fective dose of UP780 in high fat diet induced diabetic mice.
10 times the effective dose (2000 mg/kg) were selected in
the current study to evaluate the impact of UP780 in the
blood glucose level of diseased and normal mice. The com-
position UP780, comprised of 4% aloesin and 96% aloe vera
and hence a dose of 80 mg/kg and 1920 mg/kg, respec-
tively, were used for this study. The positive control group
received 5 mg/kg Glyburide. Treatment lasted for 4 weeks.
Research grade de-ionized water was used for suspending
test compounds. The positive control, Glyburide, was first
dissolved in DMSO and mixed with 0.25% of methylcel-
lulose (Spectra, Lot# 116H0857) and 0.5% of Tween 20
(Sigma, Lot # 036 K00961) at 10%. Test compounds were
repeatedly vortexed between gavages to maintain consistent
dosing. The carrier vehicle treated animals received de-
ionized water only. No detectable sign of irritation was ob-
served from drug or vehicle administration.Fasting glucose, triglyceride and plasma insulin
Fasting blood glucose and triglyceride were taken at pre-
induction, week-0 (baseline), week-2 and week-4 after
treatment of overnight fasted mice. Plasma insulin levels
were determined at pre-induction, baseline (week-0) and
week-4.
Oral glucose tolerance test (OGTT)
Oral glucose tolerance test (OGTT) was conducted 4-
week after onset of treatment [14,15]. On the test day,
animals were fasted for 5 hours and received oral admin-
istration of glucose at a dose of 2 g/kg. Blood glucose
levels were determined at time 0 (before glucose injec-
tion), and at 30, 60, 90, and 120 minutes post glucose
delivery. Blood samples were obtained from the tail
Assays
Blood glucose levels were measured using the IQ blood
glucose monitor with prestige test strips (Walgreen, Home
Diagnostics, Inc., Ft. Lauderdale, FL). Total triglyceride
levels were measured using the CardioChek Analyzer with
PTS panels test strips (Polymer Technology System, Inc,
Indianapolis, IN). Plasma insulin levels were measured
with an ELISA kit and accompanied protocol for insulin
(Crystal Chem - Chicago, IL). In brief, a mouse insulin
ELISA kit was purchased from Crystal Chemical (Cat#
90080) to test the insulin content of mouse plasma. The
provided sample diluent (95 μL) was dispensed into each
well of a 96-well antibody-coated microplate. Samples and
insulin standards (5 μL) were added to the wells in dupli-
cate and plates were incubated for 2 hours at 4°C. Each
well was then washed five times with the provided wash
buffer. The anti-insulin enzyme conjugate (100 μL) was
added to each well and the microplate was incubated at
room temperature for 30 minutes. Each well was washed
seven times with the provided wash buffer and the enzyme
substrate (100 μL) was then added to each well. The mi-
croplate was incubated at room temperature for 40 mi-
nutes before adding enzyme reaction stop solution
(100 μL) to each well. Each plate was read on a Wallac
Victor2 microplate reader at A450 with A570 values sub-
traction. Insulin concentration of the samples was calcu-
lated using the standard curve created by the insulin
standards. Blood was collected by tail vein and spun down
for plasma.
Statistical analysis
Data were analyzed using Sigmaplot (Version 11.0). The
results are represented as mean ± one S.D. Statistical sig-
nificance between groups was calculated by means of
single factor analysis of variance followed by a paired
t-test. P-values less or equal to 0.05 (P ≤ 0.05) were con-
sidered as significant. When normality test failed, for
non-parametric analysis, data were subjected to Mann-
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way analysis of variance on ranks for ANOVA. A con-
ventional trapezoid rule was used to determine area
under the curve (AUCt0-120) for glucose tolerance test.
Results
Mice administered a single intraperitoneal injection of
alloxan monohydrate at a dose of 150 mg/kg showed pro-
gression of type-I diabetes symptoms (Figure 2). As seen
from the data in Figure 2, fasting blood glucose levels were
reduced versus vehicle treatment following two weeks of
oral treatment with Glyburide (39.1% reduction), UP780
(39.1% reduction), aloesin (14.5% reduction), and Qmatrix
(19.6% reduction). Similarly, after 4-weeks of oral treat-
ment with Glyburide, UP780, UP394 and Qmatrix, a
21.4%, 35.9%, 11.6% and 17.2% reduction in fasting blood
glucose was measured for each respective treatment group
compared to the vehicle control group. Only UP780
and glyburide showed statistically significant reduction
in blood glucose level at both weeks 2 (P = 0.00001,
P = 0.003, respectively) and week-4 (P = 0.0001, P = 0.01,
respectively). Qmatrix treated animals showed statistically
significant decrease in blood glucose level at week 2
(P = 0.01). Fasting blood glucose levels for UP780 or
vehicle treated non-diabetic normal mice, i.e., without
alloxan administered, were unaffected at each time points
monitored.
From oral glucose tolerance test (OGTT) data, it was
observed that mice treated with 2000 mg/kg of UP780
or 5 mg/kg glyburide showed significantly improved
clearance of blood glucose at each time point monitored
versus vehicle treated diabetic mice (Table 1). Other
treatment groups showed similar blood glucose clea-
rance to that of vehicle after oral glucose load. Normal
mice treated with vehicle or UP780 showed equivalent






























Figure 2 Fasting blood glucose level. Insulin dependent diabetes was in
monohydrate at a dose of 150 mg/kg to CD-1 mice. Mice (n = 15/group) w
blood glucose levels at pre-induction, week-0 (baseline), week-2 and week-treatment groups. As illustrated in area-under-the curve
(AUCt0-t120) of blood glucose levels from the OGTT
data, UP780 has statistically significant low levels of
blood glucose than either aloesin or Qmatrix (Figure 3).
Similarly statistical significant reductions in total trigly-
ceride level were observed both at week-2 and week-4
for mice treated with UP780. However, these triglyceride
reductions were statistically significant only at week-2
for aloesin and week-4 for Qmatrix. In contrast, the
values were unaffected for non-diabetic mice treated
either vehicle or UP780 (Table 2).
Plasma insulin levels were also measured to assess dis-
ease progression and severity. As presented in Table 3,
post alloxan-induction plasma insulin levels were found
to be the same or lower than pre-induction plasma insu-
lin levels across all treatment groups. After four weeks
of treatment, a similar trend of increased plasma insulin
level was observed for all treatment groups including
vehicle except for aloesin treated animals. The aloesin
treatment group at week-4 showed a 4.8% reduction
in insulin levels from pre-treatment baseline values.
However, this increase of plasma insulin level for
alloxan-induced diabetic animals treated with glyburide
and UP780 at week-4 was doubled to that observed in
the vehicle plus alloxan control group.
Discussion
Significant reports have demonstrated the glucose lowe-
ring effect of Aloe plant in animal models. For instance,
reductions in fasting blood glucose and triglyceride
levels [16], improved liver gluconeogenesis and im-
proved lipid profiles [17,18], decreased oxidative brain
damage [19,20] decreased lipid peroxidation in kidney
[21] and liver [22] in streptozotocin induced diabetic
rats; improved insulin resistance and impaired glucose












duced by administering a single intraperitoneal injection of alloxan
ere fasted overnight before measurements were taken for fasting
4 after treatment. Data are expressed as mean ± SD. * P≤ 0.05.
Table 1 Oral glucose tolerance test blood glucose values
Blood glucose (mg/dl)
Group Dose (mg/kg) T0 T30 T60 T90 T120
Vehicle (-alloxan) 0 91.9 ± 4.9 125.2 ± 5.3 114.3 ± 6.4 93.4 ± 7.9 98.3 ± 5.4
UP780 (-) 2000 90.5 ± 4.2 113.7 ± 5.9 108.5 ± 4.0 95.1 ± 4.1 85.3 ± 3.3
Vehicle (+alloxan) 0 452.6 ± 18.9 518.0 ± 18.1 492.0 ± 22.6 486.1 ± 23.6 431.9 ± 21.2
Glyburide (+) 5 355.8 ± 21.6* 472.7 ± 28.2 438.5 ± 28.4 441.7 ± 35.1 398.7 ± 19.1
UP780 (+) 2000 289.9 ± 24.2* 382.9 ± 21.0* 331.2 ± 33.0* 339.7 ± 34.5* 315.1 ± 34.9*
UP394 (+) 80 400.2 ± 39.0 432.9 ± 33.0 483.4 ± 44.3 462.9 ± 47.5 442.1 ± 48.0
Qmatrix (+) 1920 374.7 ± 36.0 494.4 ± 32.0 447.5 ± 36.6 458.2 ± 43.0 443.2 ± 42.0
Insulin dependent diabetes was induced by administering a single intraperitoneal injection of alloxan monohydrate at a dose of 150 mg/kg to CD-1 mice. Oral
glucose tolerance test (OGTT) was conducted 4-week after onset of treatment. On the test day, animals (N = 15/group) were fasted for 5 hours and received oral
administration of glucose at a dose of 2 g/kg. Blood glucose levels were determined at time 0 (before glucose injection), and at 30, 60, 90, and 120 minutes post
glucose delivery. Blood samples were obtained from the tail. Data are expressed as mean ± SD. * P ≤ 0.05.
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reported.
In humans, hypoglycemic and hypolipidemic in Aloe
vera gel preparation combined with psyllium seed husks
[26], reduced blood glucose and triglyceride level in
women treated with aloe vera gel alone [27] or men in
combination with glibenclamide [28], lower fasting blood
glucose levels when Aloe vera latex is given to non-
insulin dependent diabetic patients [7], decreased levels
of total serum cholesterol, triglycerides, and low-density
lipoproteins when whole-leaf Aloe vera extract adminis-
tered patients with hyperlipidemia [29], significant re-
ductions in HbA1c, fructosamine, fasting glucose, and
insulin when Aloe vera inner leaf gel powder standar-
dized with 2% aloesin given to patients with prediabetes
or metabolic syndrome [30] and anti-hyperglycemic and
anti-hypercholesterolemic for hyperlipidemic type 2 dia-
























Figure 3 Area-under-concentration curve value of glucose in oral glu
was conducted 4-week after onset of treatment. On the test day, animals (
of glucose at a dose of 2 g/kg. Blood glucose levels were determined at tim
post glucose delivery. Blood samples were obtained from the tail. Data are
determine area under the curve (AUCt0-120) for glucose tolerance test. * P ≤It is very unusual though for either animal or human
studies of natural ingredients in diabetes to adequately
describe the composition used, including botanical spe-
cies, plant part, active components and preparation, and
to include an assessment of the dose. Similarly, activity
of aloe as a glucose lowering agent could be affected by
1) processing 2) parts of the Aloe used 3) animal models
selected and 4) structure and content of active compo-
nents. Likewise some bioactive components such as
chromones of Aloe are limited to the rinds of the plant
and the manufacture processes usually removes them
with other anthraquinone compounds [4]. Hence the
current study was conducted to evaluate glucose lower-
ing activity of a defined composition (UP780) of Aloe
vera inner leaf gel powder (Qmatrix) with aloe chro-
mones (aloesin) in insulin dependent alloxan induced










cose tolerance test (AUC (t0-t120)). Oral glucose tolerance test (OGTT)
N = 15/group) were fasted for 5 hours and received oral administration
e 0 (before glucose injection), and at 30, 60, 90, and 120 minutes
expressed as mean ± SD. A conventional trapezoid rule was used to
0.05.




Pre-induction Post-induction Week-2 Week-4
(Mean + SE) (Mean + SE) (Mean + SE) (Mean + SE)
Vehicle (-alloxan) 0 125.1 ± 10.7 90.1 ± 3.7 119.7 ± 4.6 126.9 ± 10.6
UP780 (-) 2000 118.1 ± 8.5 92.3 ± 3.6 128.7 ± 6.4 110.5 ± 5.5
Vehicle (+alloxan) 0 141.1 ± 7.3 111.5 ± 37.6 167.8 ± 20.0 144.0 ± 14.2
Glyburide (+) 5 135.3 ± 32.0 134.6 ± 37.5 135.6 ± 48.4 163.1 ± 38.8
UP780 (+) 2000 133.5 ± 7.8 117.5 ± 10.0 124.0 ± 8.8* 124.3 ± 8.2*
UP394 (+) 80 135.2 ± 8.2 121.3 ± 16.1 116.6 ± 8.41* 128.2 ± ±11.7
Qmatrix (+) 1920 130.5 ± 10.1 101.4 ± 7.3 119.7 ± 17.1 113.8 ± 30.3*
Insulin dependent diabetes was induced by administering a single intraperitoneal injection of alloxan monohydrate at a dose of 150 mg/kg to CD-1 mice.
Measurements for fasting blood triglyceride were taken at pre-induction, week-0 (baseline), week-2 and week-4 after treatment. Data are expressed as mean ± SD.
*P ≤ 0.05.
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alloxan monohydrate at a dose of 150 mg/kg per day
showed type 1 diabetes phenotype. Both UP780 and gly-
buride improved fasting blood glucose levels and glucose
tolerance, and increased insulin levels to a greater extent
than the UP780 constituents, aloesin and Qmatrix.
Plasma insulin level was also measured to estimate
degree of disease progression and severity in alloxan in-
duced diabetes model. Post induction plasma insulin
level was found lower than pre-induction across treat-
ment groups including vehicle treated mice except for
non-diabetic mice treated with vehicle or UP780. After
28 days of daily oral treatment, a similar trend in
increase plasma insulin level was observed for all treat-
ment groups including vehicle except UP394 treated
animals that showed 4.8% reduction from baseline. An
increase in plasma insulin levels was also seen for
vehicle treated, though less than 50% that seen with
UP780 and glyburide. This result with vehicle treated
mice suggests regeneration of beta-cells or compen-
satory conversion of alpha-cells to produce insulin ac-






Vehicle (-alloxan) 0 1.25 ± 0.27
UP780 (-) 2000 0.99 ± 0.14
Vehicle (+alloxan) 0 1.78 ± 0.27
Glyburide (+) 5 1.87 ± 0.33
UP780 (+) 2000 1.96 ± 0.31
UP394 (+) 80 2.48 ± 0.5
Qmatrix (+) 1920 1.89 ± 0.28
Insulin dependent diabetes was induced by administering a single intraperitoneal i
Measurements for plasma insulin were taken at pre-induction, week-0 (baseline), an
change of treatment. ↑ increase from post induction, ↓ decrease from post inductioThe increase in plasma insulin level observed for
UP780 treated non-diabetic mice was consistent to that
of vehicle treated non-diabetic mice. In week 4, the
plasma insulin level of mice with no alloxan injection
was 7.5 - 9.6 fold higher than that of the vehicle control
mice with alloxan. This surge of plasma insulin level
could be the result of metabolic compensation occurred
after fasting in response to hypoglycemia. However,
neither UP780 nor vehicle affects blood glucose level of
healthy mice. Substantiating our finding Okyar et al.
[33], have reported the neutral effect of Aloe vera leaf
pulp and gel extracts on blood glucose level of non-
diabetic rats.
Possibly UP780 could partially incurred its activity in
this model through protection and/or stimulation of
existing beta-cells to produce increased level of insulin.
Clearly interestingly though, an unexpected synergy was
observed from the combination of aloesin with aloe poly-
saccharidein that the beneficial effects seen with UP780
treatment exceed that predicted based on simply summing
the effects observed for each of its constituents. The re-
duction in fasting blood glucose level of diabetic mice inin (ng/ml)
Post-induction Week-4 % change
after treatment(Mean + SE) (Mean + SE)
1.23 ± 0.29 4.26 ± 0.36 246.3 ↑
0.99 ± 0.27 4.12 ± 0.39 316.2 ↑
1.50 ± 0.34 1.99 ± 0.24 32.7 ↑
1.10 ± 0.15 1.76 ± 0.50 60.0 ↑
1.48 ± 0.33 2.37 ± 0.41 60.1 ↑
1.68 ± 0.48 1.60 ± 0.37 4.8 ↓
1.50 ± 0.21 1.69 ± 0.32 12.7 ↑
njection of alloxan monohydrate at a dose of 150 mg/kg to CD-1 mice.
d week-4 after treatment. Data are expressed as mean ± SD as well as percent
n.
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potential antidiabetic activity. UP780, comprised of 4%
aloesin and 96% aloe vera, could have assisted surviving
β-cells to resist the oxidative damage or prevent further
damage caused by alloxan. Alloxan, as a cytotoxic agent to
the insulin-secreting β cells of the pancreas, effectively in-
duces insulin dependent phenotypes that resemble type 1
diabetes or post-beta cell “burnout” type 2 diabetes. In a
way, the daily administration of UP780 would lead to the
presence of known anti-oxidants such as aloesin and aloe
polysaccharides as a shield providing an antioxidant ac-
tivity to the β-cells of the islets of Langerhans from the
destruction caused by superoxide radicals derived from
alloxan [10,11,16]. In addition, the possibility of glyburide
enhancing β-cells responsiveness to glucose has also been
reported [34]. This mechanism of action could also be
another possibility of UP780 to alleviate hyperglycemia;
however, further detailed investigation mainly focused on
the mode of action of UP780 could shed a better un-
derstanding how the composition be better utilized in
targeting the pathogenesis of diabetes. In fact some have
suggested that hypoglycemic activity of aloe observed in
alloxan induced insulin dependent mouse model could be
associated with its radical scavenging activity [23,35-37] or
stimulate synthesis and/or release of insulin from beta-cell
of pancreases [6].
Parallel to our result, Ghannnam et al. [7] showed that
glibenclamide and aloe have statistically significant im-
pact in reducing fasting blood glucose level in diabetic
mice induced by alloxan. In this study, diabetic mice
were given 10 mg/kg and 500 mg/kg of glibenclamide
and aloe, respectively, twice per day for 14 days. Fasting
blood glucose level was found significantly lower for
both treatment groups after 3 days of treatment; how-
ever, after a week only the aloe treated mice showed the
significance. In another study conducted by Ajabnoor
(1990) also showed that when aloe was given for 4 days
at 500 mg/kg twice per day, significant reduction in fas-
ting blood glucose level were observed in alloxan in-
duced diabetic mouse.Conclusion
Clinically it has been reported that UP780 can result in
a statistically significant reduction in HbA1C, fasting
blood glucose, fructosamine and plasma insulin level
[34]. In addition to the data depicted here, previously
we have shown that UP780 could improve impaired glu-
cose and insulin resistance in high-fat diet-induced and
db/db non-insulin dependent diabetic mouse models.
Therefore, UP780, a standardized Aloe chromone based
composition, could possibly be considered as a natural
supplement alternative to maintain healthy blood glu-
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